Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00147914 · ClinicalTrials.gov registry record · Phase 4
Comparison Study Between Cefdinir & Amoxicilline/Clavulanate in Acute Sinusitis and Assessment of Quality of Life
A Phase 4 study of Acute Bacterial Sinusitis, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT00147914 is a Phase 4 study of Acute Bacterial Sinusitis that has completed, run by University of Chicago. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00147914, a Phase 4 study of Acute Bacterial Sinusitis, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a comparison between two commonly used antibiotics (Cefdinir vs. Amoxicillin/Clavulanate) in patients with acute sinus infection, surveying quality of life. The hypothesis is that the two treatments would be at the least equivalent based on clinical outcome measures of improvement in quality of life.
Conditions Studied
Interventions
- DRUG Cefdinir (drug)
- DRUG amoxicillin/clavulanate
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-02 |
| Est. Completion | 2017-02-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00147914
The ClinicalTrials.gov registry entry for NCT00147914 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Bacterial Sinusitis appearing as the primary indexed condition, and to 2 interventions - of which Cefdinir (drug) is the first listed.
NCT00147914 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00147914 about?
NCT00147914 is a clinical study titled "Comparison Study Between Cefdinir & Amoxicilline/Clavulanate in Acute Sinusitis and Assessment of Quality of Life". This study is a comparison between two commonly used antibiotics (Cefdinir vs. Amoxicillin/Clavulanate) in patients with acute sinus infection, surveying quality of life. The hypothesis is that the two treatments would be at the least equivalent based on clinical outcome measures of improvement in q...
What is the current status of trial NCT00147914?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2005-02. Estimated completion is 2017-02-18.
What conditions does trial NCT00147914 study?
This clinical trial studies the following conditions: Acute Bacterial Sinusitis.
What interventions are being tested in trial NCT00147914?
The interventions under investigation include: Cefdinir (drug) (DRUG), amoxicillin/clavulanate (DRUG).
Who is sponsoring clinical trial NCT00147914?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00147914 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.